The Medicines Company (NASDAQ:MDCO) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
announced financial results for the three months and year ended
December 31, 2016. The full text of the press release issued in
connection with the announcement is furnished as Exhibit 99.1 to
this Current Report on Form 8-K.
not be deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934 (the Exchange Act) or otherwise subject to
the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933 or the Exchange Act, except as expressly set forth by
specific reference in such a filing.
furnished, and not filed:
|
99.1
|
Press release dated February 28, 2017>entitled The
Medicines Company Reports Fourth-Quarter and Full-Year 2016>Business and Financial Results |
About The Medicines Company (NASDAQ:MDCO)
The Medicines Company is a global biopharmaceutical company. The Company’s marketed products include Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Ionsys (fentanyl iontophoretic transdermal system), Kengreal (cangrelor), Minocin (minocycline) for injection, and Orbactiv (oritavancin). Its pipeline of acute and intensive care hospital products in development include ABP-700, ALN-PCSsc, Carbavance and MDCO-216. It sells a ready to use formulation of Argatroban and has a portfolio of over 10 generic drugs, which is referred as acute care generic products. It sells over three acute care generic products, including midazolam, ondansetron and rocuronium. The Company’s products include Angiomax, which is a direct thrombin inhibitor; Cleviprex, which is a calcium channel blocker; Ionsys, which is a patient-controlled analgesia system; Kengreal, which is an antiplatelet agent; Minocin IV, which is a tetracycline-class antibiotic, and Orbactiv, which is an antibiotic. The Medicines Company (NASDAQ:MDCO) Recent Trading Information
The Medicines Company (NASDAQ:MDCO) closed its last trading session up +1.16 at 53.22 with 2,008,844 shares trading hands.
